Stock AnalizGH Research PLC GHRS
Biotechnology: Pharmaceutical Preparations · IPO 2021 · data as of November 13, 2026
GH Research PLC (GHRS) is a healthcare company listed in the US with a market value of about $1.3B.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -17%.
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — |
| Net income | -$48M | -$39M | -$36M | -$22M | -$9M | -$446000 | -$310000 |
| Free cash flow | -$44M | -$42M | -$33M | -$26M | -$15M | -$330000 | -$289000 |
| EPS (diluted) | $-0.70 | $-0.57 | $-0.52 | $-0.33 | $-0.13 | $-0.01 | $-0.00 |
| Net margin | — | — | — | — | — | — | — |
| ROIC | -21.7% | -28.1% | -18.8% | -12.2% | -5.5% | -7.9% | -77.5% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 9 analysts is $42.89, 125% above the current price; targets range from $38.00 to $65.00; the consensus rating is “Strong buy”; expected EPS is $-1.14 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does GH Research pay a dividend?
Not currently.
Is GH Research a good stock to buy?
We do not give buy or sell advice. GH Research scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.